Migraine is a common and often debilitating neurological condition characterized by recurring headaches and other sensory disturbances [3]. It represents a significant global health burden, impacting individuals' quality of life and productivity [3, 8]. While acute treatments address individual attacks, preventive therapies aim to reduce the frequency, intensity, and duration of migraine episodes, ultimately improving long-term management [7]. Despite their importance, preventive treatments have historically been underutilized [2, 7]. However, recent advances in understanding migraine's underlying mechanisms have led to a transformation in the treatment landscape, offering new and more targeted options [1, 3, 7].
When to Consider Preventive Migraine Treatment
Preventive migraine treatment is typically considered when migraine attacks are frequent, significantly disabling, or when acute treatments are ineffective, poorly tolerated, or used excessively [1]. The goal of prevention is to minimize the impact of migraine on daily life, reduce the need for acute medications, and prevent the progression of the condition [7]. Choosing the right preventive strategy requires an individualized approach, often involving a collaborative discussion between the patient and their healthcare provider [5]. This shared decision-making process helps manage expectations and determine the most effective and appropriate treatment plan [5].
Traditional Preventive Medications
For many years, migraine prevention relied on medications originally developed for other conditions, such as high blood pressure, depression, or epilepsy [1, 6]. These "traditional" oral preventive treatments have been shown to be effective for many individuals. According to the American Academy of Neurology (AAN), strong evidence supports the use of medications like metoprolol, timolol, propranolol (beta-blockers), divalproex sodium, sodium valproate, and topiramate (anti-seizure medications) for migraine prevention [2]. Other options with strong recommendations from the Canadian Headache Society (CHS) include amitriptyline (an antidepressant), gabapentin, and candesartan [2]. While these medications can be very helpful, they are not migraine-specific and can sometimes be associated with side effects, leading to challenges with adherence for some patients [6].
The Impact of CGRP-Targeting Therapies
The most significant recent advance in migraine prevention has been the development of monoclonal antibodies (mAbs) that target the calcitonin gene-related peptide (CGRP) or its receptor [1, 4, 6]. CGRP is a molecule known to play a crucial role in the development of migraine pain [1, 4, 6]. By blocking CGRP or its receptor, these new therapies specifically interrupt a key pathway involved in migraine attacks [4, 6].
These CGRP-targeting medications are administered via injection, either subcutaneously (under the skin) or intravenously (into a vein), typically on a monthly or quarterly schedule [1]. Clinical trials have demonstrated their high efficacy and good tolerability [1, 4]. They are currently recommended for use when at least two traditional preventive therapies have proven inadequate [1]. While initial clinical trials showed favorable safety profiles, some real-world studies have reported higher rates of adverse events than initially observed [1]. These migraine-specific treatments represent a significant step forward, offering benefits even to individuals who previously did not respond to non-specific preventive medications [7].
Other Emerging and Non-Pharmacologic Options
Beyond CGRP-targeting therapies, research continues into other novel drug classes, such as selective 5-hydroxytryptamine (5-HT)1F receptor agonists, which also target specific migraine pathways [4, 6]. Additionally, non-pharmacologic interventions, including neuromodulation devices, are being explored as preventive options [1]. For individuals seeking complementary approaches, certain supplements have received strong recommendations based on available evidence. These include riboflavin (Vitamin B2), coenzyme Q10, and magnesium citrate [2]. It is important to discuss the use of any supplements with a healthcare provider to ensure they are appropriate and safe for your individual situation.
Partnering with Your Healthcare Provider
Given the evolving landscape of migraine treatment, an individualized approach is essential [5]. Managing migraine effectively requires a long-term partnership between the patient and their clinician [5]. Healthcare providers, including primary care physicians, general neurologists, and headache specialists, play a vital role in diagnosing migraine, discussing all available treatment options, and helping patients manage expectations [5]. Together, through shared decision-making, patients and clinicians can determine the most effective and appropriate strategy to control migraine attacks and ease the burden of this complex neurological disease [5].
Sources
- Preventive Migraine Treatment. (Continuum (Minneapolis, Minn.), 2021) PubMed
- Preventive Migraine Treatment. (Continuum (Minneapolis, Minn.), 2015) PubMed
- Current Trends in Management of Migraine: A Review of Current Practice and Recent Advances. (CNS & neurological disorders drug targets, 2026) PubMed
- Emerging drugs for migraine treatment. (Expert opinion on emerging drugs, 2015) PubMed
- Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment. (Journal of primary care & community health, 2020) PubMed
- Emerging drugs for migraine treatment: an update. (Expert opinion on emerging drugs, 2018) PubMed
- Advances in migraine prevention. (The Lancet. Neurology, 2026) PubMed
- Overview of migraine treatment. (Pain management, 2012) PubMed